Compare PTON & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PTON | ADPT |
|---|---|---|
| Founded | 2012 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.5B |
| IPO Year | 2019 | 2019 |
| Metric | PTON | ADPT |
|---|---|---|
| Price | $6.33 | $17.56 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 10 |
| Target Price | $9.68 | ★ $16.60 |
| AVG Volume (30 Days) | ★ 8.2M | 2.1M |
| Earning Date | 02-05-2026 | 02-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,455,600,000.00 | $252,754,000.00 |
| Revenue This Year | $1.53 | $50.86 |
| Revenue Next Year | $1.42 | $0.53 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 42.57 |
| 52 Week Low | $4.63 | $6.26 |
| 52 Week High | $10.25 | $20.76 |
| Indicator | PTON | ADPT |
|---|---|---|
| Relative Strength Index (RSI) | 45.77 | 55.74 |
| Support Level | $6.40 | $15.45 |
| Resistance Level | $7.02 | $18.39 |
| Average True Range (ATR) | 0.35 | 0.84 |
| MACD | 0.04 | 0.15 |
| Stochastic Oscillator | 36.27 | 68.50 |
Peloton Interactive Inc operates an interactive fitness platform. It operates its business in two reportable segments: Connected Fitness Products and Subscription. Connected Fitness Product derives revenue from the portfolio of Connected Fitness Products and related accessories, as well as Precor-branded fitness products, delivery and installation services, Peloton Bike portfolio rental products, extended warranty agreements, branded apparel, and commercial service contracts. Subscription revenue is derived from monthly Subscription fees. The company generates maximum revenue from the Subscription segment. Geographically, the company derives a majority of its revenue from North America and the rest from International markets.
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).